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Summary. The nuclear data required for the production
and endotherapeutic application of radionuclides are outlined.
The three types of therapeutic radionuclides, viz. β−-emitters,
α-emitters and Auger electron emitters, are considered and
the role of some β+-emitters in therapy planning is discussed.
The status of available data is reviewed.
1. Introduction
Radiation therapy has gained an important place in medicine.
It is mostly performed using external beams of electrons,
X-rays, γ -rays from radioactive sources (e.g. 60Co), high-
energy γ -rays from accelerators, or hadrons (neutrons, pro-
tons, heavy ions, etc.). The use of electrons and photons
constitutes conventional therapeutic practice, and the data
needed are well documented. The rationale of hadron ther-
apy and the associated data needs are treated well in this
issue (cf. contributions by Jones, Wambersie, Haight, and
Chadwick).
In addition to external radiation therapy, some radioiso-
topes are used internally to achieve the therapeutic effect.
This could involve introducing a radioisotope in a given part
of the body (e.g. joints, organ, tumour, etc.) either mech-
anically or via a biochemical pathway. The mechanical
introduction takes place through injection of conglomer-
ates or colloids (e.g. in joints) or as solids in the form of
seeds or stents. This form of therapy is often known as
brachytherapy. The use of a biochemical pathway to de-
liver a therapeutic radioisotope to a specific organ is termed
as endoradiotherapy. This type of radiotherapy is a unique
cancer treatment modality. It is systemic and non-invasive.
The uptake and retention in the tumour can be assessed
with a tracer study prior to administering a therapeutic
dose. On the other hand, there are also several associated
problems, such as, the exact range of the ionising radi-
ation, the in vivo stability of the radiotherapeutical, the
possibility of immuno chemical changes, etc. Many aspects
of endoradiotherapy have been discussed [cf. Refs. 1–11].
In this article, the nuclear data aspect is treated in some
detail.
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2. Criteria for choice of a radionuclide for
therapeutic studies
The major criteria for the choice of a radionuclide for en-
dotherapeutic use are suitable decay characteristics and suit-
able biochemical reactivity. As regards decay properties,
the desired half-life is between 6 h and 7 d and the emit-
ted corpuscular radiation should have a suitable linear en-
ergy transfer (LET) value and range in the tissue. The ratio
of non-penetrating to penetrating radiation should be high.
The daughter should be short-lived or stable. As regards
biochemical reactivity, the situation is similar to that for di-
agnostic radiopharmaceuticals. However, the stability of the
therapeutical is demanded over a much longer period than
that in the case of a diagnostic pharmaceutical. The basis for
successful endoradiotherapy thus incorporates
(i) Good and selective concentration and prolonged reten-
tion of the radiotherapeutical in the tumour, and
(ii) Minimum uptake in normal tissue.
As a result of the above mentioned criteria, the choice falls
on about 30 radionuclides. Most of them are β−-emitters but
several of them are α- and Auger electron emitters. In re-
cent years a few β+-emitters have also found some limited
therapeutic application.
3. Radioactive decay data
The half-life (i.e. the physical half-life) of a radioisotope
is important. However, in endoradiotherapy of greater im-
portance is the biological half-life, which determines the
retention of the radiotherapeutical in the organ. The physi-
cal half-life is generally well known; the biological half-life
needs to be determined for each individual system via tracer
experiments.
The ranges of various types of emitted corpuscular radi-
ation in the tissue are shown in Fig. 1 [cf. 8,11]. The Auger
electrons have a range of about 10µm and can have a ther-
apy effect only if they reach the cell nucleus, e.g. by bringing
the radioactive source atom to the DNA. The α-particles, on
the other hand, have a range of about 100 µm and can have
a therapy effect already if they reach the cell membrane,
e.g. by attachment of the α-emitter to a receptor ligand. The
β−-particles have ranges of about 1 mm and more, depend-
ing upon their energies. They can lead to therapy effects
even if they reach the cell environment. Evidently, achiev-
ing the therapy effect with Auger electrons and α-particles
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Fig. 1. Correlation between type and energy of corpuscular radiation
and the range in tissue (adapted from Refs. [8, 11]).
involves a very subtle approach and demands great skills
in biochemistry, radiopharmacology and radiotherapeutical
production and application. In the case of β−-particles, the
therapeutic applications have been more straightforward,
though not very specific.
The methods of internal dose calculation have received
extensive attention and well-known computer codes, known
as MIRD codes, are now available. As regards diagnostic ra-
dionuclides, calculations are done to keep the radiation dose
as low as possible. In the case of therapeutic radionuclides,
on the other hand, the dose has to be high enough to achieve
the therapeutic effect.
In endoradiotherapy, the radioactive decay data thus play
a very important role (see also [4, 8]). In particular, a know-
ledge of the energy and intensity of the ionising radiation
is crucial. The effect of low-energy but high intensity elec-
trons, emitted following EC and IT, is not negligible. For
widely used therapeutic radioisotopes therefore all sources
of secondary electrons must be taken into account. The ac-
curacy in dosimetry depends on the accuracy of the available
decay and biochemical data. In general, the available decay
database is extensive [cf. 12,13]. The Auger electron spec-
tra, on the other hand, are often not accurately known.
4. Production data
The criteria for the production of therapeutic radioisotopes
are generally the same as those for diagnostic radioisotopes,
i.e. high radionuclidic purity, high radiochemical purity and
high specific radioactivity (cf. contribution by Qaim, this
issue). The three types of therapeutic radionuclides, viz. β−-
emitters, α-emitters and Auger electron emitters, are treated
below separately.
4.1 β−-emitters
The number of β−-emitters of therapeutic relevance is rela-
tively large. The commonly used radionuclides are listed in
Table 1. In each case the main decay and production data are
outlined. To date, 131I has been most extensively utilized, but
in recent years many of the other isotopes listed in Table 1
have been finding enhanced application.
Besides the commonly used β−-emitters, several other
β−- and β+-emitters have found isolated therapeutic appli-
cations. A few examples of β−-emitters are: 47Ca (T1/2 =
4.5 d), 47Sc (T1/2 = 3.4 d), 77As (T1/2 = 1.6 d), 105Rh (T1/2 =
1.5 d), 159Gd (T1/2 = 18.5 h), 161Tb (T1/2 = 6.9 d), 165Dy
(T1/2 = 2.4 h), 166Dy (T1/2 = 3.4 d), 169Er (T1/2 = 9.4 d),
171Er (T1/2 = 7.5 h), 199Au(T1/2 = 3.1 d), etc. Some of the
β+-emitters occasionally used in endoradiotherapy are: 48V
(T1/2 = 16.9 d), 52Mn (T1/2 = 5.6 d), 124I (T1/2 = 4.2 d), etc.
The therapeutic applications of 124I are increasing.
Most of the β−-emitters are produced in a nuclear reactor,
and data are needed on neutron capture, sequential neutron
capture, (n, z) processes and fission yields. Some special
radionuclides like 67Cu and 186Re are produced using both
a reactor and an accelerator.
In a nuclear reactor, the (n, γ ) process is commonly uti-
lized for production purposes. The excitation function of
a typical (n, γ ) reaction is shown in Fig. 2 [cf. 14]. The
major interest is in the low energy region. The specific ra-
dioactivity achieved is rather low. In general, it is limited by
the cross section of the (n, γ ) reaction, the isotopic abun-
dance of the target isotope and the neutron flux in the re-
actor. With a view to enhancing the specific radioactivity,
either the β−-decay daughter of an (n, γ )-product is used,
e.g. 110Pd(n, γ ) 111m,gPd → 111Ag, or a generator system is
developed, e.g. 90Sr → 90Y and 188W → 188Re. Occasionally
an alternative route of production is looked for. This may in-
volve the use of an (n, p) reaction in a fast neutron field or
the utilization of a cyclotron. The two aspects are considered
individually below.
The (n, p) reaction is occasionally utilized to produce
therapeutic radionuclides in the medium and heavy mass
regions, besides its use in the light mass region. Two demon-
strated examples are 67Zn(n, p)67Cu and 89Y(n, p)89Sr.
The product yield in a fission neutron spectrum is low,
since the threshold of the (n, p) reaction is rather high,
i.e. between 2 and 6 MeV. The excitation functions of the
67Zn(n, p)67Cu and 89Y(n, p)89Sr reactions, measured radio-
chemically [15, 16], are shown in Fig. 3. If an intense fast
neutron field is used, the cross section averaged over the
whole spectrum is much higher than for a fission spectrum.
A suitable example is the breakup neutron field, produced by
14–15 MeV deuterons on beryllium [cf. 17]. Since presently
available high-intensity commercial machines are capable of
providing such fast neutron fields, the production of 67Cu
and 89Sr via the respective (n, p) reaction appears very ad-
vantageous. Another possibility is the use of a spallation
Fig. 2. Excitation function of the 152Sm(n, γ )153Sm reaction. The data
were normalized relative to the very precise measurements at the ther-
mal neutron energy (0.025 eV) and at 30 keV (taken from [14]).
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Table 1. Nuclear data relevant to some commonly used therapeutic radionuclides.
Radio- T1/2 Emax of Eγ Production route Cross section
nuclide emitted particle in keV in mb or remarks a,b
in MeV (Iγ in %)
β−-emitters
32P 14.3 d 1.7 (β−) 31P(n, γ ) 160
32S(n, p) 70
67Cu 2.6 d 0.6 (β−) 185 (45) 67Zn(n, p) 1.07
RbBr(p, spall) 1.6 at 800 MeV
68Zn(p, 2p) 10.0 at 71 MeV
89Sr 50.5 d 1.5 (β−) 88Sr(n, γ ) 5.8
89Y(n, p) 0.31
90Y 2.7 d 2.3 (β−) 89Y(n, γ ) 1250
235U(n, f )90Sr Ycum: 5.89%
90Sr → 90Y generator
(28.6 a)
111Ag 7.5 d 1.0 (β−) 342 (6) 110Pd(n, γ )111m,gPd → 111Ag 733
(5.5 h, 23.4 min)
131I 8.0 d 0.6 (β−) 364 (81) 130Te(n, γ )131m,gTe → 131I 230
(25 min, 1.3 d)
235U(n, f )131I Ycum = 2.84%
153Sm 1.9 d 0.8 (β−) 103 (28.3) 152Sm(n, γ ) 206×103
166Ho 1.1 d 1.8 (β−) 81 (6.2) 165Ho(n, γ ) 61×103
164Dy(n, γ )165Dy(n, γ )166Dy (2.7;3.5)×106
(2.4 h)
166Dy → 166Ho generator
(3.4 d)
177Lu 6.7 d 0.5 (β−) 208 (11) 176Lu(n, γ ) 1780×103
186Re 3.8 d 1.1 (β−) 137 (8.5) 185Re(n, γ ) 114×103
186W(p, n) 100 at 10 MeV c
186W(d,2n) 430 at 13 MeV c
188Re 17.0 h 2.0 (β−) 155 (14.9) 186W(n, γ )187W(n, γ )188W (36;70)×103
(23.7 h)
188W → 188Re generator
(69.0 d)
α-emitters
211At 7.2 h 5.9 (α) 209Bi(α, 2n) 825 at 28 MeV c
(211Po) (0.52 s) 7.5 (α)
213Bi 46 min 5.9 (α) 440 (16.5) Gen. 225Ac (10.0 d) radioactive waste
1.4 (β−) (see below)
(213Po) (4.2µs) 8.3 (α)
225Ac 10.0 d 5.8 (α) 100 (1.7) 229Th α→ 225Ra radioactive waste
(7880 a)
225Ra β
−→ 225Ac
(14.8 d)
226Ra(p, 2n) unknown
(1600 a)
X-ray and Auger electron emitters
67Ga 3.3 d Auger electrons 93 (37) 67Zn(p, n) 640 at 11 MeV c
68Zn(p, 2n) 727 at 20 MeV c
103Pd 17.0 d Auger electrons 103Rh(p, n) 600 at 10 MeV c
natAg(p, x) 40 at 28 MeV c
111In 2.8 d Auger electrons 245 (94) 111Cd(p, n) 791 at 12 MeV c
112Cd(p, 2n) 1025 at 19 MeV c
125I 60.1 d Auger electrons 35 (6.7) 124Xe(n, γ )125Xe → 125I 165×103
(16.9 h)
a: Neutron capture data are for thermal neutrons and the (n, p) cross sections are fission neutron spectrum averaged values.
The fission yields are cumulative yields (Ycum).
b: For charged particle induced reactions the cross section at a suitable energy is given.
c: For this reaction the full excitation function has been measured.
neutron source, generated by high energy protons on a heavy
target. In the spectrum, there is a sufficiently strong fast
neutron component (with En ≥ 10 MeV), which is ideally
suited for (n, p) reactions. Besides 67Cu and 89Sr, several
other therapeutic radioisotopes like 47Sc, 77As, 105Rh, 153Sm,
159Gd, 166Ho, 177Lu, 188Re, etc. could also be produced in
fast neutron fields via (n, p) reactions on enriched target
isotopes.
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Fig. 3. Excitation functions of 67Zn(n, p)67Cu and 89Y(n, p)89Sr reac-
tions (adapted from Refs. [15, 16]). From the given curves the average
cross sections 〈σ〉 for 14 MeV d(Be) breakup neutron spectrum were
deduced. Those values as well as the values for a fission spectrum (FS)
are given in the insert. The 〈σ〉 values for the d(Be) breakup neutron
spectrum are by a factor of about 6 higher than those for FS.
In recent years attempts have been underway to utilize
small and medium-sized cyclotrons to produce some known
β−-emitting therapeutic radionuclides via alternative routes
as well as to develop other radionuclides of potential ther-
apeutic interest. Two important examples are furnished by
67Cu and 186Re. 67Cu is almost an ideal therapeutic radionu-
clide. It is produced via an (n, p) reaction in a nuclear
reactor (see above), via the spallation of RbBr or via the
68Zn(p, 2p) reaction at a high energy accelerator [cf. 18,19].
A recent study showed [20] that the 70Zn(p, α)67Cu reac-
tion over the proton energy range Ep = 18→ 12 MeV, using
highly enriched 70Zn as target material, can be used to pro-
duce 67Cu at a small cyclotron. The radionuclide 186Re is
produced generally via the 185Re(n, γ )-reaction. Since it
forms very stable co-ordination compounds (similar to tech-
netium), it has a great therapeutic potential. The main lim-
itation is its specific radioactivity. Two alternative routes
making use of the 186W(p, n)186Re and 186W(d, 2n)186Re re-
actions are therefore attracting great interest. The excitation
functions have been measured [cf. 21–23] and the yields are
known (cf. Fig. 4). The yield of 186Re via the (d, 2n) reac-
Fig. 4. Calculated integral yields of 186Re (T1/2 = 3.8 d) formed via pro-
ton and deuteron induced reactions on 186W. The relatively low yields
of 186Re suggest that the very long-lived high-spin isomer is produced
in relatively high yields (adapted from [22]).
tion at 15 MeV is much higher than via the (p, n) reaction at
19 MeV [cf. 22].
Despite the above mentioned four production approaches
to increase the specific activity of a β−-emitter (viz. use of
a β−-decay daughter of an (n, γ )-product, development of
a generator system, application of an (n, p) reaction or use
of a cyclotron), there are a large number of cases where there
is no alternative to an (n, γ ) reaction. Most of those cases re-
fer to rare-earth isotopes which, in recent years, have been
attracting enhanced attention [cf. 24] due to their affinity for
bone matrix. Fortunately, the (n, γ ) cross sections in that
mass region are quite high, so that the specific radioactivity
achieved is not as low as in many other cases. If an enriched
target isotope and a higher flux reactor are used, the achiev-
able specific radioactivity may still be enhanced.
4.2 α-emitters
The commonly used α-emitting radionuclides are listed in
Table 1. 211At is important and is produced via the (α, 2n)
reaction on bismuth and the data are well known [cf. 25].
225Ac is a promising radioisotope, both in itself and as
a generator for 213Bi. It is obtained as a decay product of
229Th, occurring in the nuclear waste. An interesting pro-
duction route is the reaction 226Ra(p, 2n)225Ac [cf. 26]. Its
cross section has hitherto not been measured and consti-
tutes a very challenging task. A few other potentially useful
α-emitters are 149Tb (T1/2 = 4.1 h), 212Bi (T1/2 = 1.0 h), 223Ra
(T1/2 = 11.4 d), 224Ra (T1/2 = 3.7 d), etc.
The use of α-emitting radionuclides in endoradiother-
apy has been under review almost ever since the discovery
of radioactivity. In recent years it has gained more impe-
tus. It should, however, be pointed out that the application
of α-emitters demands stringent quality control tests. While
working with 211At, for example, a very careful check of the
irradiation conditions is mandatory. The α-particle energy
to induce the 209Bi(α, 2n)-reaction is kept at 28.0 MeV oth-
erwise the 209Bi(α, 3n)210At reaction would also occur. Its
decay product leads to the α-emitting 210Po (T1/2 = 138.4 d)
and would cause excessive extra radiation dose. The field of
radiotherapy with α-particles is expected to develop further.
Consequently the need for both accurate decay and produc-
tion data will increase.
4.3 X-ray and Auger electron emitters
Some of the X-ray and Auger electron emitters which have
found therapeutic use are listed in Table 1. Evidently, both
reactors and cyclotrons are utilized for production purposes.
However, the cyclotrons appear to have a higher potential
since both X-ray and Auger electron emitters are generally
neutron deficient.
The radioisotopes 67Ga and 111In are known more as
diagnostic radionuclides since they emit suitable γ -rays.
However, their potential as Auger electron emitting ther-
apeutic radionuclides is being increasingly realized. Of
particular interest is 125I since it is almost a pure Auger
electron emitter and is conveniently attached to a DNA
molecule. The radionuclide 103Pd has gained great signifi-
cance in recent years. The production data were measured
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recently [cf. 27,28] and another study is reaching comple-
tion under a Jülich/Debrecen cooperation.
Development work on Auger electron emitters is con-
tinuing. The recently studied radionuclide 140Nd (T1/2 =
3.4 d) [cf. 29] is a pure Auger electron emitter. Similarly
the radionuclides 195mPt (T1/2 = 4.0 d) and 193mPt (T1/2 =
4.3 d) are promising Auger electron emitters. However, the
presently used production methods ((n, γ ) and (n, n′γ ) pro-
cess) give very low yields of the latter two radioisotopes.
Since in both cases high spin isomers are involved, the 3He-
and α-particle induced reactions may be advantageous. In
general, Auger electron therapy has a great potential [cf. 30]
but calls upon more fundamental work in all related areas.
The radionuclide 117mSn (T1/2 = 13.6 d) is interesting
since here conversion electrons, instead of X-rays and Auger
electrons, are effective in palliative therapy. Evidently,
all data related to conversion electron emission would be
needed for dose calculation. The radionuclide is produced
via the (n, n′γ )-process [cf. 31,32]. An alternative method
of production involves the 3He- and α-particle induced reac-
tions on In and Cd [33].
5. Some special considerations in studies relevant
to production data
Most of the special considerations in nuclear data studies re-
lated to the production of diagnostic radioisotopes (cf. con-
tribution by Qaim, this issue), such as, the search for al-
ternative production routes, the role of increasing incident
particle energy, and the check of isomeric impurities, are
valid also for the therapeutic radionuclides. Furthermore,
cross section measurements relevant to the formation of pure
β−-emitters and Auger electron emitters are often very chal-
lenging since very clean radiochemical separations and thin
source preparation are required. The counting methods may
involve low-level β−-counting, X-ray spectrometry or liquid
scintillation counting. Thus interdisciplinary techniques are
of great significance in these studies.
5.1 Analogue positron emitters: therapy planning
A relatively new development in endoradiotherapy with
β−-emitters, initiated at Jülich [cf. 34,35], pertains to in-
ternal dosimetry through the use of a β+-emitting ana-
logue of the therapy radionuclide. A quantitative tracer study
via PET, prior to therapeutic application, enables therapy
planning and an accurate calculation of the dose distri-
bution during the therapy; such calculations had hitherto
been done only empirically. A few analogue β+-emitters of
β−-emitting therapy radionuclides are: 64Cu for 67Cu, 83Sr
for 89Sr, 86Y for 90Y, 124I for 131I, etc. Evidently, the produc-
tion and application of those non-conventional β+-emitters
calls upon considerable nuclear data and other development
work.
6. Status of nuclear data and conclusions
As discussed above, most of the radionuclides commonly
used in endoradiotherapy are β−-emitters. They are mainly
produced in a nuclear reactor and the status of nuclear data
is generally good [cf. 36–39]. However, to date no evaluated
data file in this respect has been developed. Regarding the
β−- and β+-emitters which have hitherto found only limited
application, or which are of potential interest, the cross sec-
tion data base varies from case to case. For reactor-produced
radionuclides it is good; for cyclotron produced radioiso-
topes, however, more work may be needed. In particular,
an evaluation of the existing data is required. The avail-
able information on the established α-emitter 211At is good.
Similarly the decay and production data of the commonly
used Auger electron emitters are well known. For potentially
useful α-emitters and Auger electron emitters, however, the
available information both on decay and production data is
often not detailed enough. Since endoradiotherapy is a fast
developing field, and new radionuclides emitting the lat-
ter two types of corpuscular radiation are being constantly
suggested, the need for nuclear data is enhancing. Consid-
erable amount of experimental, theoretical and evaluation
work would be necessary to meet those needs. The experi-
mental work is often very challenging since a quantitative
measurement of the radioactivity via X-ray spectrometry or
Auger electron counting is needed. Theory and evaluations
face difficulties since isomeric states with highly converted
isomeric transitions are involved. In the latter case, a detailed
information on the conversion coefficients is also needed.
In short, a concerted effort is called for to build a reliable
database relevant to production and application of therapeu-
tic radionuclides.
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